title: [Antiischemic efficacy of trimetazidine in patients with ischemic heart disease, stable angina pectoris and disturbances of carbohydrate metabolism].
abstract: OBJECTIVE
  To compare antiischemic effects of trimetazidine in patients with stable angina pectoris with and without disturbances of carbohydrate metabolism.
  
  
  METHODS
  Patients with ischemic heart disease, stable class II-III angina pectoris and reproducible positive results of on-treatment exercise tests (n=40, mean age 56.7-/+1.95 years, 37 men) with normal carbohydrate metabolism (group 1, n=20) and with disturbances of carbohydrate metabolism (group 2, n=20).
  
  
  METHODS
  All patients in addition to individually selected antianginal therapy were given trimetazidine (60 mg/day) for 2 months. Bicycle exercise tests were repeated after 1 and 2 months. Patient's diaries were used for registration of anginal attacks and nitroglycerine consumption.
  
  
  RESULTS
  Addition of trimetazidine was associated with significant (p<0.005) prolongation of exercise duration until 1 mm-ST depression in both groups. Exercise duration was 553-/+10.5 and 555-/+10.2 s (p>0.05) at baseline, 657-/+15.3 and 695-/+10.1 s (p<0.05) after 2 months in groups 1 and 2, respectively. Other effects of trimetazidine in groups 1 and 2 included increases of total work performed during exercise test (by 14 and 22%, respectively), decreases in numbers of patients with ST depression (by 40, p<0.05, and 50%, p<0.05, respectively), numbers of anginal attacks (by 30, p<0.001, and 43%, p<0.001, respectively) and nitroglycerine pills (by 13%, p<0.001 and 51%, p<0.001, respectively). The decrease in supplemental nitroglycerine consumption was significantly more pronounced in group 2 (p<0.0001). There was no significant increment in double product in both groups.
  
  
  CONCLUSIONS
  Antiischemic effect of trimetazidine was greater in patients with angina pectoris and disturbances of carbohydrate metabolism than in similar patients without such disturbances. KEY WORDS. trimetazidine; diabetes, type II, ischemic heart disease; angina pectoris.
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Fedotkina
authors.forename: E P
authors.initials: EP
authors.lastname: Panchenko
mesh_terms: D000787:Angina Pectoris / Q000150:complications* / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications* / Q000188:drug therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D014665:Vasodilator Agents